Long-Term Outcomes in Patients With Recurrent Ovarian Cancer and Exceptional Response to PARP Inhibitors

Gastrointestinal Cancer

Comparing short- and long-term survivors in metastatic pancreatic cancer: Insights into patient and disease profiles impacting systemic therapy outcomes

Eur J Cancer

Graus MUJE, van Diepen AE, Broekman T, van Eijck CWF, van Hooft JE, Homs MYV, Wumkes ML, Wilmink JW, de Hingh IHJT, Valkenburg-van Iersel LBJ, van der Geest LGM, Vos-Geelen J, Dutch Pancreatic Cancer Group (DPCG)

doi: 10.1016/j.ejca.2026.116263

Genitourinary Cancer

Long-term outcomes following a 5-year recurrence-free interval in non-muscle-invasive bladder cancer

BJU Int

Hjort PB, Jensen JB, Ernst A

doi: 10.1111/bju.70267

Gastrointestinal Cancer

Long-Term Outcomes of Patients With BRCA+ or PALB2+ Pancreatic Cancer Treated With Maintenance Rucaparib: A Secondary Analysis of a Nonrandomized Clinical Trial

JAMA Oncol

Reiss KA, Xia M, Akamandisa M, D'Andrea K, Wubbenhorst B, Lord CJ, Pettitt SJ, Tutt ANJ, Brown TJ, O'Hara MH, Schneider C, Teitelbaum U, Hannan Z, Hood R, Tondon R, Vonderheide RH, Domchek SM, Nathanson KL

doi: 10.1001/jamaoncol.2026.0870

Genitourinary Cancer

Impact of Intraprostatic Simultaneous Integrated Boost on Long-Term Outcomes in Unfavorable Intermediate-Risk Prostate Cancer Treated With Dose-Escalated Radiotherapy and Short-Term Androgen Deprivation Therapy

Prostate

Onal C, Elmali A, Demirhan B, Senturk E, Erpolat P, Guler OC

doi: 10.1002/pros.70167

Breast Cancer

Patient-reported outcomes in the SERENA-6 trial of camizestrant plus CDK4/6 inhibitor in patients with advanced breast cancer and emergent ESR1 mutations during first-line endocrine-based therapy

Ann Oncol

Mayer EL, Bidard FC, Park YH, Janni W, Ma C, Cristofanilli M, Iwata H, Bianchini G, Kalinsky K, Chia S, Brufsky A, Fasching PA, Nowecki Z, Chen SC, Pascual J, Moreau L, Ruiz-Borrego M, Shai A, Karadurmus N, Sohn JH, Zhu Y, Leddin I, Miralles MS, Bartlett CH, Turner N

doi: 10.1016/j.annonc.2025.10.006

Central Nervous System Tumors

Association of proton pump inhibitor use with outcome of patients with recurrent glioblastoma

Eur J Cancer

Le Rhun E, Sain D, van den Bent M, Franceschi E, Tabatabai G, Wick W, Preusser M, Gorlia T, Weller M

doi: 10.1016/j.ejca.2026.116225

Lung, Respiratory and Thoracic Cancer

Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in patients with advanced non-small-cell lung cancer: a systematic review and reconstructed individual patient data meta-analysis

Lancet Oncol

Di Federico A, Stumpo S, Mantuano F, De Giglio A, Lo Bianco F, Pecci F, Alessi JV, Wang X, Sperandi F, Melotti B, Gelsomino F, Skoulidis F, Garassino MC, Peters S, Awad MM, Ardizzoni A, Ricciuti B

doi: 10.1016/S1470-2045(25)00429-2

Breast Cancer

Association of recurrence patterns and outcome with HR and HER2 status in patients with resected brain metastases from breast cancer

Int J Cancer

Weller J, Katzendobler S, Thiele F, Riesberg A, Harter PN, Klauschen F, Wuerstlein R, Schoenecker S, Escudero MP, Forbrig R, Thon N, Ringel F, Weller M, Le Rhun E, Stoecklein VM

doi: 10.1002/ijc.70407

Leukemia

Long-term outcomes in FLT3-mutated acute myeloid leukemia after frontline hypomethylating agent, venetoclax and a FLT3 inhibitor

Haematologica

Short NJ, Loghavi S, Yilmaz M, Karrar O, Kim K, Dinardo CD, Kadia TM, Maroun M, Borthakur G, Issa GC, Jabbour J, Oran B, Shpall EJ, Popat U, Patel KP, Routbort M, Konopleva M, Ravandi F, Kantarjian H, Daver N

doi: 10.3324/haematol.2025.288553

Related content